NeoImmuneTech, Inc. Presents Data in Three Posters At Society for Immunotherapy of Cancer Annual Meeting
November 16, 2021 at 07:00 am
Share
NeoImmuneTech, Inc. presented new data from two clinical trials evaluating the company?s lead asset NT-I7, a novel T cell amplifier, in three posters at the Society for Immunotherapy of Cancer annual meeting. The data come from two cohorts of the Phase 2a portion of a Phase 1b/2a clinical trial evaluating NT-I7 in combination with Merck?s anti-PD-1 therapy KEYTRUDA for the treatment of patients with relapsed/refractory advanced solid tumors, as well as a Phase 1 investigator-initiated trial evaluating NT-I7 following adjuvant chemotherapy and radiation in patients with high-grade gliomas . The data shows that the combination of NT-I7 and pembrolizumab was well tolerated and showed early anti-tumor activity in patients with checkpoint inhibitor -naive relapsed/refractory pancreatic and microsatellite-stable colorectal cancers, two immune-cold tumor types. The interim analysis of the phase 2 met the primary endpoint of overall response rate in these cohorts. The median follow-up of the efficacy data was ~5.8 months in the MSS-CRC Cohort and approx. 4.6 months in the Pancreatic Cancer Cohort. Three immune partial responses by iRECIST were observed, including one partial response by RECIST 1.1 in 17 evaluable MSS-CRC patients, as well as one iPR/PR observed in 17 evaluable pancreatic cancer patients. The pancreatic cancer responder was confirmed to have a microsatellite-stable tumor. Responses were first observed at weeks 12, 18, and 24 post-first dose. Increase of T cell infiltration in the tumor microenvironment were observed in the responders, a key indicator that the tumor microenvironment is shifting from immune-cold to immune-hot. Importantly, an even greater magnitude of increase in stem-cell memory CD8+ T cells was observed in the blood. The data shows that NT-I7 is well tolerated following chemoradiation therapy in HGG patients. Notable ALC increases were observed, with more prominent increases in patients dosed at the 540?g/kg or higher levels of NT-I7. Marked increase of Tscm was also observed, in this case in absence of a checkpoint inhibitor. Durable progression-free survival was noted in MGMTp unmethylated HGG patients, a sub-group who often have a poorer prognosis. Six out of eight patients treated at the therapeutic dose of 720?g/kg or higher are continuing on in the study.
NeoImmuneTech, Inc. is a clinical-stage T cell-focused biopharmaceutical company. The Company is engaged in the discovery and development of immuno-therapeutics. Its lead asset includes NT-I7 (efineptakin alfa), which is a T Cell Amplifier. NT-I7 is a human IL-7 (Interleukin-7) fusion protein that overcomes the limitations of endogenous IL-7. The IL-7 domain promotes T cell development, which plays a role in the immune response. The N-terminus of the IL-7 domain overcomes its structural instability and enables mass production of NT-I7. NT-I7 is a clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications. It is conducting multiple clinical trials of NT-I7 in multiple indications both as a monotherapy and in combination with other therapeutics, such as checkpoint inhibitors and other. Its products include NIT-106, NIT-109, NIT-110, NIT-119, NIT-120, NIT-104, NIT-107, NIT-112, NIT-105, NIT-108, NIT-113, NIT-114, NIT-115, NIT-116 and NIT-A01.